Peringatan Keamanan

Doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.L42290

Adalimumab

DB00051

biotech approved experimental

Deskripsi

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.A39984,A39999 It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA.A39983 This drug is frequently known as Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses.A39983

Several biosimilars to adalimumab. Adalimumab-atto was the first adalimumab biosimilar approved by the FDA in 2016.L44953 Adalimumab-adaz was approved by the FDA on October 31, 2018.L4799 Other biosimilars include adalimumab-fkjp - which was approved in July 2022 -,L42495 adalimumab-bwwd - which was approved in August 2022 -,L42935 and adalimumab-aacf - which was approved in October 2023.L49101 A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available.L45643,L45818

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.[L35370]
Volume Distribusi The distribution volume (Vss) ranged from 4.7 to 6.0 L following intravenous administration of doses ranging from 0.25 to 10 mg/kg in RA patients.[L35370]
Klirens (Clearance) The single-dose pharmacokinetics of adalimumab in RA patients were determined in several studies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of adalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, there was no evidence of changes in clearance over time in RA patients.[L35370]

Absorpsi

The maximum serum concentration (Cmax) and the time to reach the maximum concentration (Tmax) were 4.7 ± 1.6 ?g/mL and 131 ± 56 hours respectively, following a single 40 mg subcutaneous administration of adalimumab to healthy adult subjects. The average absolute bioavailability of adalimumab estimated from three clinical studies after a single 40 mg subcutaneous dose of adalimumab was 64%. The pharmacokinetics of adalimumab showed a linear pattern over the dose range of 0.5 to 10.0 mg/kg following a single intravenous dose.L35370

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Adalimumab is most likely removed by opsonization via the reticuloendothelial system.A40006

Interaksi Obat

1344 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.
Etanercept The risk or severity of infection can be increased when Adalimumab is combined with Etanercept.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Adalimumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Adalimumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Adalimumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Adalimumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Adalimumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Adalimumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Adalimumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemtuzumab ozogamicin.
Pegaspargase The risk or severity of adverse effects can be increased when Adalimumab is combined with Pegaspargase.
Interferon beta-1b The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon beta-1b.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfacon-1.
Rituximab The risk or severity of infection can be increased when Adalimumab is combined with Rituximab.
Basiliximab The risk or severity of adverse effects can be increased when Adalimumab is combined with Basiliximab.
Muromonab The risk or severity of adverse effects can be increased when Adalimumab is combined with Muromonab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Adalimumab is combined with Ibritumomab tiuxetan.
Tositumomab The risk or severity of adverse effects can be increased when Adalimumab is combined with Tositumomab.
Alemtuzumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Alemtuzumab.
Alefacept The risk or severity of adverse effects can be increased when Adalimumab is combined with Alefacept.
Efalizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Efalizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit).
Interferon alfa-2b The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfa-2b.
Daclizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Adalimumab is combined with Phenylalanine.
Cladribine Adalimumab may increase the immunosuppressive activities of Cladribine.
Amsacrine The risk or severity of adverse effects can be increased when Adalimumab is combined with Amsacrine.
Bleomycin The risk or severity of adverse effects can be increased when Adalimumab is combined with Bleomycin.
Chlorambucil The risk or severity of adverse effects can be increased when Adalimumab is combined with Chlorambucil.
Raltitrexed The risk or severity of adverse effects can be increased when Adalimumab is combined with Raltitrexed.
Mitomycin The risk or severity of adverse effects can be increased when Adalimumab is combined with Mitomycin.
Floxuridine The risk or severity of adverse effects can be increased when Adalimumab is combined with Floxuridine.
Tioguanine The risk or severity of adverse effects can be increased when Adalimumab is combined with Tioguanine.
Dexrazoxane The risk or severity of adverse effects can be increased when Adalimumab is combined with Dexrazoxane.
Streptozocin The risk or severity of adverse effects can be increased when Adalimumab is combined with Streptozocin.
Trifluridine The risk or severity of adverse effects can be increased when Adalimumab is combined with Trifluridine.
Gemcitabine The risk or severity of adverse effects can be increased when Adalimumab is combined with Gemcitabine.
Epirubicin The risk or severity of adverse effects can be increased when Adalimumab is combined with Epirubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Adalimumab is combined with Chloramphenicol.
Lenalidomide The risk or severity of adverse effects can be increased when Adalimumab is combined with Lenalidomide.
Altretamine The risk or severity of adverse effects can be increased when Adalimumab is combined with Altretamine.
Cisplatin The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin.
Oxaliplatin The risk or severity of adverse effects can be increased when Adalimumab is combined with Oxaliplatin.
Propylthiouracil The risk or severity of adverse effects can be increased when Adalimumab is combined with Propylthiouracil.
Pentostatin The risk or severity of adverse effects can be increased when Adalimumab is combined with Pentostatin.
Linezolid The risk or severity of adverse effects can be increased when Adalimumab is combined with Linezolid.
Clofarabine The risk or severity of adverse effects can be increased when Adalimumab is combined with Clofarabine.
Methimazole The risk or severity of adverse effects can be increased when Adalimumab is combined with Methimazole.
Sulfasalazine The risk or severity of adverse effects can be increased when Adalimumab is combined with Sulfasalazine.
Temozolomide The risk or severity of adverse effects can be increased when Adalimumab is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Adalimumab is combined with Penicillamine.
Mechlorethamine The risk or severity of adverse effects can be increased when Adalimumab is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Adalimumab is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Adalimumab is combined with Carboplatin.
Dactinomycin The risk or severity of adverse effects can be increased when Adalimumab is combined with Dactinomycin.
Hydroxyurea The risk or severity of adverse effects can be increased when Adalimumab is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Adalimumab is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Adalimumab is combined with Topotecan.
Melphalan The risk or severity of adverse effects can be increased when Adalimumab is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Adalimumab is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Adalimumab is combined with Flucytosine.
Procarbazine The risk or severity of adverse effects can be increased when Adalimumab is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Adalimumab is combined with Arsenic trioxide.
Mitoxantrone The risk or severity of adverse effects can be increased when Adalimumab is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Adalimumab is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Adalimumab is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Adalimumab is combined with Nelarabine.
Stepronin The risk or severity of adverse effects can be increased when Adalimumab is combined with Stepronin.
Castanospermine The risk or severity of adverse effects can be increased when Adalimumab is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Adalimumab is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Adalimumab is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Adalimumab is combined with Brequinar.
Afelimomab The risk or severity of adverse effects can be increased when Adalimumab is combined with Afelimomab.
Interferon alfa The risk or severity of adverse effects can be increased when Adalimumab is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Adalimumab is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Adalimumab is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Golimumab The risk or severity of infection can be increased when Adalimumab is combined with Golimumab.
Belatacept The risk or severity of adverse effects can be increased when Adalimumab is combined with Belatacept.
Pralatrexate The risk or severity of adverse effects can be increased when Adalimumab is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Adalimumab is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Adalimumab is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Adalimumab is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Adalimumab is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Adalimumab is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Obinutuzumab.
Secukinumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Secukinumab.
Siltuximab The risk or severity of adverse effects can be increased when Adalimumab is combined with Siltuximab.
Blinatumomab The risk or severity of adverse effects can be increased when Adalimumab is combined with Blinatumomab.
Dinutuximab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dinutuximab.
Tixocortol The risk or severity of adverse effects can be increased when Adalimumab is combined with Tixocortol.
Peginterferon beta-1a The risk or severity of adverse effects can be increased when Adalimumab is combined with Peginterferon beta-1a.
Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Adalimumab is combined with Antilymphocyte immunoglobulin (horse).
Tepoxalin The risk or severity of adverse effects can be increased when Adalimumab is combined with Tepoxalin.
Ixekizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ixekizumab.
Ravulizumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ravulizumab.

Target Protein

Tumor necrosis factor TNF

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17359217
    Kivitz A, Segurado OG: HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices. 2007 Mar;4(2):109-16. doi: 10.1586/17434440.4.2.109.
  • PMID: 18360621
    Mease PJ: Adalimumab in the treatment of arthritis. Ther Clin Risk Manag. 2007 Mar;3(1):133-48.
  • PMID: 12884458
    Scheinfeld N: Adalimumab (HUMIRA): a review. J Drugs Dermatol. 2003 Aug;2(4):375-7.
  • PMID: 16011443
    Scheinfeld N: Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005 Jul;4(4):637-41. doi: 10.1517/14740338.4.4.637.
  • PMID: 17149453
    Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH: Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006 Nov 20;5:e8.
  • PMID: 23205329
    Hinterberger L, Muller CS, Vogt T, Pfohler C: Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb). 2012 Dec;2(1):6. doi: 10.1007/s13555-012-0006-6. Epub 2012 May 12.
  • PMID: 28653357
    Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29.
  • PMID: 30873466
    Farrugia M, Baron B: The role of TNF-alpha in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res. 2016 Sep 15;2(3):84-90. eCollection 2016 Nov 10.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 385 • International brands: 3
Produk
  • Abrilada
    Solution • 40 mg / 0.8 mL • Subcutaneous • Canada • Approved
  • Abrilada
    Solution • 40 mg / 0.8 mL • Subcutaneous • Canada • Approved
  • Abrilada
    Solution • 20 mg / 0.4 mL • Subcutaneous • Canada • Approved
  • Abrilada
    Solution • 10 mg / 0.2 mL • Subcutaneous • Canada • Approved
  • Abrilada
    Kit; Solution • 40 mg / 0.8 mL • Subcutaneous • Canada • Approved
  • Abrilada
    Injection, solution • 20 mg/0.4mL • Subcutaneous • US
  • Abrilada
    Injection, solution; Kit • - • Subcutaneous; Topical • US • Approved
  • Abrilada
    Injection, solution; Kit • - • Subcutaneous; Topical • US • Approved
Menampilkan 8 dari 385 produk.
International Brands
  • Amjevita — Amgen, Inc.
  • Cyltezo — Boehringer Ingelheim Pharmaceuticals, Inc.
  • Humira Pen — Abbott Laboratories

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul